SPRY financials
ARS Pharmaceuticals (SPRY) financials: revenue, profit and margins by year and quarter, the balance sheet and cash flow.
SPRY income statement, yearly
| Year | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 | $84.28M | $63.85M | -$179.45M | -$171.30M | -1.74 |
| 2024 | $89.15M | $68.59M | -$3.08M | $8.00M | 0.08 |
| 2023 | $30.00K | $30.00K | -$67.52M | -$54.37M | -0.57 |
| 2022 | $1.32M | -$15.80M | -$35.52M | -$34.68M | -0.87 |
| 2021 | $5.51M | $5.29M | -$19.45M | -$20.24M | -0.70 |
| 2020 | $17.84M | $3.77M | -$469.00K | -$1.06M | -0.03 |
- SPRY revenue was $84.28M in fiscal 2025, net income -$171.30M.
Updated 2026-11-07 11:54 UTC